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Abstract
Human TRIM5a potently restricts particular strains of murine leukemia viruses (the so-called N-tropic strains) but not others
(the B- or NB-tropic strains) during early stages of infection. We show that overexpression of SUMO-1 in human 293T cells,
but not in mouse MDTF cells, profoundly blocks N-MLV infection. This block is dependent on the tropism of the incoming
virus, as neither B-, NB-, nor the mutant R110E of N-MLV CA (a B-tropic switch) are affected by SUMO-1 overexpression. The
block occurred prior to reverse transcription and could be abrogated by large amounts of restricted virus. Knockdown of
TRIM5a in 293T SUMO-1-overexpressing cells resulted in ablation of the SUMO-1 antiviral effects, and this loss of restriction
could be restored by expression of a human TRIM5a shRNA-resistant plasmid. Amino acid sequence analysis of human
TRIM5a revealed a consensus SUMO conjugation site at the N-terminus and three putative SUMO interacting motifs (SIMs)
in the B30.2 domain. Mutations of the TRIM5a consensus SUMO conjugation site did not affect the antiviral activity of
TRIM5a in any of the cell types tested. Mutation of the SIM consensus sequences, however, abolished TRIM5a antiviral
activity against N-MLV. Mutation of lysines at a potential site of SUMOylation in the CA region of the Gag gene reduced the
SUMO-1 block and the TRIM5a restriction of N-MLV. Our data suggest a novel aspect of TRIM5a-mediated restriction, in
which the presence of intact SIMs in TRIM5a, and also the SUMO conjugation of CA, are required for restriction. We propose
that at least a portion of the antiviral activity of TRIM5a is mediated through the binding of its SIMs to SUMO-conjugated
CA.
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Introduction
Cells have developed many mechanisms to restrict viral
infection. The adaptative immune response provides major
protection against viral pathogens, but recently dominant-acting
inhibitory gene products, called restriction factors, have been
discovered that also play an important role in limiting host
susceptibility to viral infections. One class of such restriction
factors blocks retroviral infection by targeting the incoming capsid
protein (CA) (for review see [1]).
Early studies identified the Friend virus susceptibility factor 1
(Fv1) locus as a host gene determining the susceptibility of mice to
infection by various strains of murine leukemia viruses (MLV) [2].
Two major alleles of Fv1 were identified: Fv1
n and Fv1
b. Fv1
n
renders NIH/Swiss mice resistant to B-tropic MLV (B-MLV)
infection and Fv1
b renders BALB/c mice resistant to N-tropic virus
[3,4]. The critical difference between the N- and B-tropic MLVs
was traced to specific residues of the viral capsid (CA) protein [5–
7]. Some strains of MLV, including Moloney MLV, termed NB-
tropic, are insensitive to Fv1 restriction [4]. The restriction by Fv1
occurs early in infection, after reverse transcription but before viral
DNA integration, and is saturable by large amount of virus [8–10].
The mechanism by which Fv1 restricts MLV infection is
unknown, but it is generally presumed that Fv1 somehow
recognizes the incoming CA protein structure and prevents
normal infection.
More recently, rhesus monkey TRIM5a and human TRIM5a
were identified as intracellular restriction factors capable of
blocking infection by human immunodeficiency virus type-1
(HIV-1) and N-MLV, respectively [11–15]. TRIM5a blocks
retroviral replication early in the life cycle, after viral entry but
before reverse transcription [16–21]. The same residues of MLV
capsid determine sensitivity to the Fv1 and human TRIM5a-
mediated restriction [14,21]. Some human cell lines are able to
potently block N-MLV infection (HeLa, TE671) while others
(293T cells) do not block N-MLV or do so only weakly [20]. The
mechanism by which TRIM5a restricts infection is unclear.
TRIM5a is a member of the tripartite motif family of proteins,
characterized as having three domains: a RING domain, either
one or two B-boxes, and a coiled-coil domain [22]. The C-
terminus of TRIM5a, unlike that of most TRIMs, consists of a
B30.2 domain. This domain binds to CA molecules of incoming
retroviruses, and its sequence determines which retroviruses a
specific TRIM5a will restrict [12,14,21,23–27]. The RING
domain is a cysteine-rich zinc binding domain commonly found
in E3 ubiquitin ligases, and there is some evidence suggesting that
PLoS Pathogens | www.plospathogens.org 1 April 2011 | Volume 7 | Issue 4 | e1002019TRIM5a could be a ubiquitin ligase [28]. The B-box domains are
thought to act as protein-protein interaction domains and thereby
determine RING box ubiquitin ligase substrate specificity [29].
The coiled-coil domain has been shown to be involved in homo-
and hetero-multimerization of the TRIM proteins, and deletion of
this domain in TRIM5a completely abrogates HIV-1 and N-MLV
restriction [30–32].
SUMO proteins are small ubiquitin-related proteins that
become conjugated to cellular substrates and regulate diverse
cellular processes, including intracellular trafficking, cell cycle
progression, transcription, DNA repair and nuclear receptor
activities (for review see [33,34]). SUMO conjugation, like
ubiquitination, requires an E1 activating enzyme (in the case of
SUMO, these are AOS1-UBA2), an E2 conjugation enzyme
(UBC9) [35,36] and often an E3 ligase (RanBP2 and PIAS 1, -3
and -4/y) which recognize the substrate and determine target
specificity [37–39]. In mammals, three SUMO paralogues are
commonly expressed: SUMO-1, SUMO-2 and SUMO-3. SU-
MO-1 is distinct from SUMO-2 and SUMO-3; SUMO-2 and
SUMO-3 are 97% identical to each other but only 47% identical
to SUMO-1. SUMO-1 and SUMO-2/3 are conjugated to
different target proteins in vivo [40,41,42] and likely serve distinct
functions. SUMO proteins are usually transferred to lysines of a
UBC9 binding site motif of consensus sequence YKxE (where Y is
a hydrophobic residue and x any amino acid) [43,44], though
lysines in other contexts can be modified.
In addition to targeting different substrate proteins, the
functional properties of SUMO isoforms might also reflect their
ability to mediate distinct protein-protein interactions in vivo.
Recent work has identified specific motifs that mediate non-
covalent interactions with SUMO modified proteins [43,45,46].
The best characterized of the SUMO-interacting motifs (SIMs)
have the consensus sequence V/I/L-x-V/I/L-V/I/L or V/I/L-
V/I/L-x-V/I/L (where x is any amino acid) [46,47].
In the past few years, there have been many reports
demonstrating the involvement of SUMO conjugation in virus
replication. In some instances, conjugation of SUMO to either
viral proteins or host proteins can impair viral infection, and
hence, viruses have found ways to interfere with the pathway [48–
50]. In other instances, SUMO conjugation of viral proteins can
be essential for viral replication [41,48,51]. It has been reported
that Gag proteins from Mazon-Pfizer monkey virus, Moloney
murine leukemia virus, and HIV-1 interact with the SUMO
conjugation pathway [52–54]. Our laboratory has previously
reported that the E2 and E3 SUMO-conjugating enzymes, UBC9
and PIAS4/y, interact with the capsid (CA) protein of Moloney
murine leukemia virus (MoMLV or NB-tropic MLV). The UBC9
and PIAS4/y binding sites within CA were identified, and it was
also demonstrated that co-expression of CA and tagged-SUMO-1
proteins resulted in SUMO conjugation of CA in vivo. Mutation of
lysine residues to arginine near the UBC9 binding site and
ablation of the PIAS4/y binding site reduced or eliminated CA
SUMO conjugation, and impaired virus replication. This block
occurred in the early stages of viral infection, after reverse
transcription and before nuclear entry and viral DNA integration.
The findings suggest a role for the SUMO machinery in the early
stages of viral infection [54].
In an effort to further elucidate the relationship between the
SUMO conjugation pathway and early events of the MLV life
cycle, we tested the effects of manipulating the components of the
SUMO transfer machinery in several cell lines. Surprisingly, we
found that the normally weak N-MLV restriction by TRIM5a in
human cells is profoundly enhanced by overexpression of SUMO-
1. The presence of two SIMs in TRIM5a is required for the
enhanced N-MLV restriction. Mutation of lysines preventing CA
SUMOylation, abolish TRIM5a-mediated restriction of N-MLV.
Our data suggest a novel aspect of the TRIM5a-mediated
restriction of N-tropic MLV, in which the presences of intact
SIMs in TRIM5a, and SUMO conjugation of CA, are required
for N-MLV restriction. We propose that TRIM5a recognition of
CA is augmented by binding SUMO-modified CA via its SUMO-
interacting motif.
Results
Overexpression of human SUMO-1 enhances the block of
N-tropic MLV infection in 293T cells
To explore the significance of SUMO conjugation in the early
stages of viral infection, we transduced 293T cells with an empty
retroviral vector or a vector encoding HA-tagged versions of
human SUMO-1, SUMO-2 or SUMO-3. Pools of cell lines stably
expressing these proteins were selected. The presence of the HA-
tagged SUMO proteins was detected by Western blot (Figure 1A).
The empty vector control, HA-SUMO-1, HA-SUMO-2, and HA-
SUMO-3 overexpressing cell lines were then assayed in single
round infection experiments. The different cell lines were infected
in parallel with increasing amounts of VSV-G pseudotyped B-
(Figure 1B), N- (Figure 1C), or NB-tropic MLV (Figure 1D) virus
particles delivering a firefly luciferase reporter (B-MLV luc, N-
MLV luc and NB-MLV luc respectively). The overexpression of
HA-SUMO-1 in 293T cells reduced the infectivity of N-MLV by
an average of more than 8-fold as compared to the empty vector
cell line (Figure 1C). In contrast, SUMO-1 overexpression had no
significant effect on susceptibility to infection by B-MLV
(Figure 1B) or NB-MLV (Figure 1D). Overexpression of HA-
SUMO-2 did not affect susceptibility to infection by any of the
viruses. Overexpression of HA-SUMO-3 reduced the susceptibility
to infection by N-MLV by only 2 fold, again with no effect on
infection by B- or NB-MLV. These data show that SUMO-1
overexpression induces or enhances a block to N-MLV infection in
293T cells.
This data raised the possibility that SUMO-1 overexpression
could also block N-MLV infection in murine cells that are non-
restrictive for N-MLV, such as the Fv1-null Mus dunni tail
fibroblasts (MDTF). We transduced MDTF cells with the
retroviral vectors encoding HA-SUMO-1 used above, and
detected the presence of HA-SUMO-1 by Western blot
(Figure 2A). Overexpression of SUMO-1 in MDTF did not affect
Author Summary
TRIM5a is an intrinsic immunity protein that provides a
post-entry block of retroviral infection, which depends on
its specific ability to recognize retroviral capsid (CA).
Human TRIM5a is able to recognize and block infection by
N-tropic murine leukemia virus (N-MLV) as well as other
viruses. The exact mechanism by which TRIM5a exerts its
action is still controversial. In this study, we have identified
a new aspect of TRIM5a-mediated restriction of N-MLV: the
involvement of the SUMO conjugation machinery. SUMO
conjugation of MLV CA is an important step during viral
infection, and our data suggest that innate immunity takes
advantage of this process to restrict viral infection. We
show that human TRIM5a protein contains two SUMO
interacting motifs (SIMs) that are required for its antiviral
activity against N-MLV. We propose that at least a portion
of the antiviral activity of TRIM5a is mediated through the
binding of its SIMs to SUMO-conjugated CA.
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infection in 293T cells. A. 293T cells stably expressing an empty
vector, HA-SUMO-1, HA-SUMO-2 or HA-SUMO-3 were generated. The
presence of the overexpressed HA-tagged SUMO paralogs was
detected by Western blot using an antibody directed against the HA-
tag (upper panel), using actin as a control (bottom panel). B–D. The
293T empty vector control cell line or HA-SUMO-1, HA-SUMO-2 or HA-
SUMO-3 overexpressing cell lines were mock treated or infected with
increasing amount of VSV-G pseudotyped B-MLV luc (B), N-MLV luc (C)
or NB-MLV luc (D). Forty-eight hours after infection, luciferase activity
was measured. One representative experiment of five independent
experiments is shown. Error bars indicate standard deviation among
triplicates in the same experiment.
doi:10.1371/journal.ppat.1002019.g001
Figure 2. Overexpression of SUMO-1 in MDTF and TE671 cells.
A. Stable MDTF and TE671 cells expressing an empty vector or HA-
SUMO-1 were generated, and overexpressed HA-tagged SUMO-1 and
actin were detected by Western blot. B. The MDTF empty vector control
or HA-SUMO-1 over-expressing cell lines were mock treated or infected
with increasing amounts of VSV-G pseudotyped N-MLV luc. C. The
TE671 empty vector control cell line or HA-SUMO-1 overexpressing cell
line were mock treated or infected with increasing amount of VSV-G
pseudotyped N-MLV luc. Forty-eight hours after infection, luciferase
activity was measured. One representative experiment of three
independent experiments is shown. Error bars indicate standard
deviation among triplicates in the same experiment.
doi:10.1371/journal.ppat.1002019.g002
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(Figure 2B). This result indicates that the inhibition of N-MLV
infection by overexpression of SUMO-1 is cell-type dependent,
and could require a baseline level of restriction.
293T cells have been described as non-restrictive or very weakly
restrictive for N-MLV infection when compared to other human
cell lines such as TE671 or HeLa [20]. To test if overexpression of
SUMO-1 in other more restrictive human cells could enhance the
restriction to N-MLV, we transduced TE671 cells with retroviral
vectors encoding HA-SUMO-1 used above, and confirmed
expression by Western blot (Figure 2A). Overexpression of
SUMO-1 in TE671 cells reduced infection of N-MLV by an
average of 3 fold as compared to the empty vector cell line
(Figure 2C). This result suggests that overexpression of SUMO-1
can enhances a restriction activity present in multiple human cell
lines.
Since overexpression of SUMO-1 is enhancing restriction in
human cells, we wondered if the knock down of endogenous
SUMO-1 would be able to release restriction. We knocked down
the endogenous SUMO-1 in 293T, HeLa and TE671, then we
infected the cells with N-MLV or B-MLV luc, virus infection was
not significantly increased (data not shown). These results are very
difficult to interpret; SUMO-1 is required for early events during
infection [54] and any effect observed with the different shRNA
used was equivalent for both N-MLV and B-MLV luc infection,
although the restriction to N-MLV infection in HeLa and TE671
cells is still present.
The SUMO-1-mediated block of N-MLV is dependent on
CA residue 110
Our data show that SUMO-1 specifically blocks N-tropic
MLV and not B- or NB-tropic MLV. This suggests that the
viral capsid, and its associated tropism, is a critical determinant
of the antiviral effects of SUMO-1 on N-MLV. Capsid (CA)
protein amino acid 110 appears to be the most important
determinant of Fv-1 N (specified by R110) and B (specified by
E110) tropisms [7]. To determine if CA is also the target for the
block observed in SUMO-1-overexpressing 293T cells, we
generated a mutant version of N-MLV luc in which amino
acid 110 in CA was mutated from arginine to glutamic acid (N-
MLV luc CA R110E), a change known to convert Fv-1
sensitivity from N to B-tropism. N-MLV luc CA R110E
infection was not blocked by HA-SUMO-1 overexpression in
293T when compared with the empty vector cell line
(Figure 3A). Therefore the antiviral effects of SUMO-1 on N-
MLV are dependent on CA amino acid 110.
The SUMO-1-mediated block of N-MLV can be abrogated
by pretreatment with virus particles
The observation that the antiviral effects of SUMO-1 are CA-
dependent and cell-type specific suggests that SUMO-1 overex-
pression enhances the antiviral activity of an intrinsic restriction
factor. Human cells contain the restriction factor TRIM5a,
which confers resistance to N-MLV but not B- or NB-MLV
infection [13,20,32,55]. TRIM5a antiviral activity was found to
be dependent on CA amino acid 110 and could be abrogated
with high multiplicities of infection [20,56]. To determine
whether the SUMO-1 enhanced block could also be abrogated,
293T cells transduced with the empty vector control or HA-
SUMO-1 were pretreated with increasing amounts of N-MLV
containing a green fluorescent protein (GFP) reporter gene (N-
MLV GFP). Four hours later, the cells were superinfected with a
fixed amount of N-MLV luc. Those 293T cells expressing the
empty vector did not significantly restrict N-MLV luc infection
(Figure 1C). Pretreatment of those cells with N-MLV GFP had
little effect on the luciferase activity after infection with N-MLV
luc (Figure 3B). Pretreatment of 293T cells overexpressing HA-
SUMO-1 with N-MLV GFP at high doses, however, resulted in a
dose-dependent loss of the SUMO-1-mediated block to N-MLV
luc infection. Thus, as observed for the TRIM5a-mediated
restriction, the SUMO-1 block of N-MLV infection can be
abrogated.
The SUMO-1 block of N-MLV occurs prior to reverse
transcription
Under normal circumstances, TRIM5a blocks retroviral
replication early in the life cycle, after viral entry but before
reverse transcription [19,57]. To determine whether the block is
occurring at a similar time in the SUMO-1 overexpressing cells,
the course of viral DNA synthesis was examined by qPCR after
acute infection. 293T cells stably transduced with the empty vector
or HA-SUMO-1 were infected with N-MLV luc at two different
dilutions. The levels of amplified viral DNA products correlated
well with the levels of input virus in the empty vector control cell
line. Examination of an early step in reverse transcription, using
primers that detect the minus strand strong stop (MSS) DNA (the
first detectable product of viral DNA synthesis), revealed a
significant reduction in MSS DNA products in the SUMO-1-
overexpressing cell line as compared to the empty vector cell line
(Figure 3C, left panel). In correlation with this, very low levels of
luciferase DNA sequences, which correspond to linear fully reverse
transcribed viral DNA from our luciferase reporter (Figure 3C,
middle panel), and nuclear viral DNA forms, analyzed by
detection of the 2-LTR junction (Figure 3C, right panel) were
detected in the SUMO-1-overexpressing cell line as compared to
the empty vector cell line. These data shows that SUMO-1
overexpression resulted in an early block in the viral life cycle, at a
step prior to reverse transcription, and that the block to early
forms continues to affect later DNA forms in the course of
infection.
The SUMO-1-mediated block of N-MLV is mediated by
human TRIM5a
TRIM5a-mediated restriction of N-MLV infection is dependent
on CA amino acid 110, occurs prior to reverse transcription, and
can be saturated with high multiplicities of infection [14,20,56].
The SUMO-1 block of N-MLV infection in 293T has the same
characteristics, suggesting that TRIM5a could be mediating the
block of N-MLV by SUMO-1 overexpression.
To determine whether TRIM5a mediates SUMO-1 restriction
of N-MLV, we knocked down the expression of TRIM5a in the
HA-SUMO-1 overexpressing cell line using shRNAs specific for
the coding sequence or the 39 UTR region of human TRIM5a
mRNA (Figure 4A). An shRNA containing a scrambled,
nonsilencing (scr) sequence was used as a control. TRIM5a
mRNA was efficiently reduced by all of the targeted shRNAs
tested, as determined by qPCR (Figure 4B). Expression of all five
of the shRNAs directed specifically to the TRIM5a transcript
abolished the HA-SUMO-1 block to N-MLV luc infection
(Figure 4C), while expression of the control scr shRNA had no
effect. This result strongly suggests that human TRIM5a is
required for the SUMO-1 block of N-MLV infection.
To confirm that elimination of the SUMO-1 block to N-MLV
infection by TRIM5a shRNA was due to reduced levels of
TRIM5a and not the result of an off-target effect, we transiently
transfected a plasmid encoding a FLAG-tagged human TRIM5a
Human TRIM5a Requires SUMO Interacting Motifs
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SUMO-1/shRNA4 cell line, in which the shRNA is directed to the
39UTR region of the TRIM5a transcript. The SUMO-1 block to
N-MLV was restored when we reintroduced the shRNA-resistant
TRIM5a in the HA-SUMO-1/shRNA4 cell line (Figure 4D). We
confirmed the restored TRIM5a expression by Western blotting of
the same extracts used for the luciferase assay (Figure 4D bottom).
These results demonstrate that the block of N-MLV infection
upon SUMO-1 overexpression requires human TRIM5a.
There is a complex relationship between the SUMO and
ubiquitin pathways, and it is possible that the ubiquitin ligase
activity of the RING domain of TRIM5a is required for N-MLV
restriction upon SUMO-1 overexpression. To test this, we
generated a mutant version of TRIM5a in which cystein 15 and
18 in the first zing finger were mutated to alanine (C15A/C18A),
in the context of the FLAG-TRIM5a vector. The SUMO-1 block
to N-MLV was restored when we reintroduced the C15A/C18A
TRIM5a in the HA-SUMO-1/shRNA4 cell line (Figure 5C). This
result indicated that the RING domain E3 ubiquitin ligase activity
of TRIM5a is not required for the block of N-MLV infection upon
SUMO-1 overexpression.
SUMO-interacting motifs present in human TRIM5a are
important for restriction of N-MLV
As our data suggested an unanticipated relationship between
SUMO-1 and TRIM5a, we asked if TRIM5a contains any amino
acid motifs indicative of an interaction with the SUMO
conjugation pathway. Analysis of the TRIM5a protein sequence
revealed an N-terminal consensus site for SUMO conjugation and
three potential SUMO-interacting motifs (SIM) in the B30.2
domain (Figure 5A), motifs often identified in proteins involved in
non-covalent SUMO binding. The first potential SIM (SIM1)
consists of an ILGV hydrophobic core that is followed by a
cysteine residue. The second potential SIM (SIM2) consists of a
VIGL hydrophobic core that is juxtaposed with two acidic amino
acids (EE). The third potential SIM (SIM3) consists of an IVPL
hydrophobic core that is followed by a Ser residue. To determine
the importance of these sites to the antiviral activity of TRIM5a,
we independently mutated the consensus SUMO conjugation site
(K10R), the first SIM (SIM1mut), the second SIM (SIM2mut), and
the third SIM (SIM3mut) in the context of the FLAG-TRIM5a
vector (Figure 5B). We transiently transfected the HA-SUMO-1/
shRNA4 cell line with constructs encoding these human TRIM5a
Figure 3. Characterization of SUMO-1 block of N-MLV infection in 293T cells. A. The 293T empty vector control or HA-SUMO-1 cell lines
were infected with increasing amounts of a mutant version of N-MLV luc in which amino acid 110 of the CA protein was mutated from arginine to
glutamic acid (R110E). Luciferase activity was measured forty-eight hours post-infection. One representative experiment of three independent
experiments is shown. B. The 293T empty vector control or HA-SUMO-1 cell lines were infected with increasing amounts of VSV-G-pseudotyped N-
MLV expressing a GFP reporter, and four hours post-infection, cells were superinfected with a fixed amount of VSV-G-pseudotyped N-MLV luc.
Luciferase activity was measured forty-eight hours post-infection. One representative experiment of four independent experiments is shown. C. The
293T empty vector control or HA-SUMO-1 overexpressing cell lines were infected with undiluted (1:1) or 10-fold diluted (1:10) VSV-G-pseudotyped N-
MLV luc. Mock treated cells were included as a negative control. Total DNA was isolated twenty hours after infection, and the amount of viral DNA
synthesized in the infected cells was measured by quantitative PCR. Primers specific for the minus-strand strong stop (MSS) DNA (left panel),
Luciferase gene (middle panel) or LTR-LTR junction (right panel) were used. The values were normalized to GAPDH DNA and expressed as fold over
empty vector. Error bars indicate standard deviation among triplicates in the same experiment (A and B) or 3 different experiments (C).
doi:10.1371/journal.ppat.1002019.g003
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with N-MLV luc. Luciferase activity was measured forty-eight
hours post-infection, and TRIM5a protein expression was
confirmed by Western blotting (Figure 5C, bottom). Both wild-
type TRIM5a and K10R mutant proteins were able to restore the
block of N-MLV infection in the HA-SUMO-1/shRNA4 cell line
(Figure 5C). This suggests that SUMO conjugation of TRIM5a at
K10R is not required for restriction of N-MLV. Although
SUMOylation of TRIM5a may occur, in spite of many efforts,
we have not been able to demonstrate biochemically that human
TRIM5a undergoes SUMO conjugation (data not shown). In
contrast, the mutations in the first and second SIM sequences of
TRIM5a (SIM1mut, SIM2mut) relieves the restriction activity
(Figure 5C). The SIM3mut protein restricted N-MLV infection to
levels similar to wild type and K10R TRIM5a. These results
suggest that SIM1 and SIM2 motifs present in the B30.2 domain
of TRIM5a are important for restriction activity of TRIM5a in
the context of the 293T HA-SUMO-1 cell line.
We wondered if SUMO-1 overexpression impacted on
TRIM5a expression levels. To answer this we transiently express
FLAG-TRIM5a wild type or the mutant versions in the empty
vector control cell line or the cells that express HA-SUMO1, and
compared by Western blot the levels of TRIM5a expressed in the
2 cell lines. When SUMO-1 is overexpressed we found that there
was only 1.2-fold more wild-type and SIM3mut TRIM5a than in
the empty vector control cells, and that no change was observed
for K10R, SIM1mut or SIM2mut TRIM5a (Figure S1A and B).
Therefore, SUMO-1 overexpression has no impact on TRIM5a
expression levels.
It has been documented that exogenous expression of human
TRIM5a in permissive cells, such as Crandall feline kidney
(CRFK) fibroblast or Mus dunni (MDTF) cells, imparts a block
against N-MLV as potent as the one observed in human cells
[12,13,58]. To determine the ability of TRIM5a mutants to
inhibit infection of N-MLV in cells that do not overexpress
SUMO-1 and are permissive for N-MLV infection, we generated
Figure 4. SUMO-1 block of N-MLV infection on 293T cells is mediated by TRIM5a.A .Schematic representation of the target site of five
different shRNAs directed to the human TRIM5a messenger RNA. B. The 293T empty vector control cell line stably expressing a control scrambled
(scr) shRNA (white bar) or the HA-SUMO-1 overexpressing cell line stably expressing a control scrambled shRNA, or different shRNAs directed to
human TRIM5a mRNA (black bars), were generated. RNA was extracted, and the mRNA levels of TRIM5a were determined by quantitative PCR. The
values were normalized to GAPDH mRNA and expressed as fold over empty vector-scr. C. The 293T expressing the control scr shRNA or the different
shRNAs directed to TRIM5a mRNA were infected with a fixed multiplicity of N-MLV luc. Forty-eight hours after infection luciferase activity was
measured. D. The 293T expressing the control scr shRNA or the shRNA4 were transiently transfected with an empty plasmid or a plasmid encoding
human TRIM5a with a FLAG-tag as indicated. Twenty-four hours after transfection, cells were infected with a single dose of N-MLV luc. Forty-eight
hours after infection, luciferase activity was measured, and Western blots were performed on the same extract to verify the expression of FLAG-
TRIM5a using an anti-FLAG antibody (upper panel), an anti-HA antibody to verify the expression of HA-SUMO-1 (middle panel) and an anti-actin
antibody as a control (bottom panel). Error bars indicate standard deviation among triplicates in the same experiment.
doi:10.1371/journal.ppat.1002019.g004
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mutant Myc-tagged versions of TRIM5a. The expression levels of
the mutants were somewhat variable (Figure 5D), though
TRIM5a protein levels have not been found to correlate with
the strength of restriction in cells where TRIM5a is overexpressed
[25,58]. To measure the retroviral restriction activities of the
TRIM5a wild-type, K10R, and SIM mutants, populations of
MDTF and CRFK cells expressing these various TRIM5a
proteins were infected with increasing doses of N-MLV luc, and
the cultures were analyzed for luciferase activity. In MDTF cells,
wild-type and K10R TRIM5a restricted N-MLV. Importantly,
the SIM1mut and SIM2mut proteins were completely unable to
mediate restriction of N-MLV (Figure 5E), and the SIM3mut
showed modestly reduced restriction as compared to the wild-type
TRIM5a. As in the wild type TRIM5a overexpressing cells, both
K10R and SIM3mut, restricted N-MLV infection before reverse
transcription (Figure S2). Similar phenotypes of restriction for the
different TRIM5a mutant proteins were observed in CRFK cells
(Figure 5F). Thus, SIM1 and SIM2 of human TRIM5a are crucial
for N-MLV restriction in general, not only in the context of
SUMO-1 overexpression.
The SIMs present in human TRIM5a are conserved in several
primates orthologs (Figure S3). To determine if the SIM1 and
SIM2 are also required for restriction of N-MLV by TRIM5a of
other species, we generated the same mutations used above in the
rhesus monkey (Macaca mulatta) TRIM5a, which has been reported
to restrict N-MLV infection [15]. We generated CRFK cell lines
stably expressing either wild-type or mutant FLAG-tagged
versions of rhesus TRIM5a, and the presence of the different
rhesus TRIM5a proteins was detected by Western blot (Figure 6A).
To measure the retroviral restriction activities of the rhesus
TRIM5a wild-type, K10R, and SIM mutants, populations of
CRFK cells expressing these various proteins were infected with
increasing doses of N-MLV luc, and the cultures were analyzed for
luciferase activity. Wild-type and SIM3mut TRIM5a restricted N-
MLV. Mutant K10R showed modestly reduced restriction as
compared to the wild-type TRIM5a. Most importantly, SIM1mut
and SIM2mut rhesus TRIM5a were completely unable to mediate
restriction of N-MLV (Figure 6B). These results suggest that SIM1
and SIM2 are important for restriction activity of different
TRIM5a orthologs.
When expressed from transgenes, TRIM5a has been reported
to form large cytoplasmic bodies [11,59] or to exhibit a diffuse
reticular pattern in the cytoplasm [32]. Several groups have
demonstrated full retroviral restriction activity of TRIM5a in the
absence of detectable cytoplasmic bodies [24,32,59], while others
have shown the bodies to be highly dynamic structures that are key
intermediates in the restriction process [60,61]. We wondered if
the mutations we introduced in TRIM5a could be altering its
subcellular localization and if this possible change was the cause of
the defective restriction observed. The CRFK cell lines expressing
the TRIM5a wild-type or the different mutants were examined by
immunofluorescence using a confocal microscope. In all cases, a
punctate cytoplasmic staining pattern was observed with no
Figure 6. SUMO interacting motifs present in TRIM5a orthologs
are important for restriction activity. A. CRFK cells stably
expressing an empty vector, and FLAG-tagged wild-type rhesus TRIM5a
or K10R, SIM1mut, SIM2mut and SIM3mut mutants were generated. The
presence of the FLAG-TRIM5a proteins was detected by Western blot
using a FLAG-antibody; the presence of GAPDH was used as a control.
B. The CRFK empty vector control cell line and the indicated FLAG-
TRIM5a overexpressing cell lines were mock treated or infected with
increasing amounts of N-MLV luc. Forty-eight hours after infection,
luciferase activity was measured. One representative experiment of
three independent experiments is shown. Error bars indicate standard
deviation among triplicates in the same experiment.
doi:10.1371/journal.ppat.1002019.g006
Figure 5. SUMO interacting motifs present in human TRIM5a are important for restriction of N-MLV. A. Amino acid sequence of human
TRIM5a. The RING (blue), B-box (green), coiled-coil (yellow), B30.2 (pink) domains, and the location of a consensus SUMO conjugation site (green
letter) and three putative SUMO interacting motifs (SIM) (red letters) are indicated. The variable regions of the B30.2 domain are depicted with
horizontal bars above. B. The substitution mutations are indicated. WT: wild-type amino acid sequence; mut: mutated amino acid sequence. C. The
293T empty vector cell line expressing scr shRNA or the HA-SUMO-1 expressing scr shRNA were transfected with an empty plasmid, and the HA-
SUMO-1 expressing shRNA4 (shRNA4-TRIM5a) cells were transiently transfected with an empty plasmid or plasmids encoding FLAG-tagged wild-type
human TRIM5a or the C15A/C18A, K10R, SIM1mut, SIM2mut and SIM3mut mutants. Twenty-four hours after transfection, cells were infected with a
single dose of N-MLV luc. Forty-eight hours after infection, luciferase activity was measured and Western blotting was performed using the same
extract to verify the expression of the different FLAG-TRIM5a proteins using an anti-FLAG antibody (upper panel) and an anti-GAPDH antibody as a
control (bottom panel). D. MDTF (upper panel) and CRFK (bottom panel) cells stably expressing an empty vector, and Myc-tagged wild-type human
TRIM5a or K10R, SIM1mut, SIM2mut and SIM3mut mutants were generated. The presence of the TRIM5a-Myc proteins was detected by Western blot
using a Myc-antibody; the presence of actin was used as a control. E. The MDTF empty vector control cell line and the indicated TRIM5a-Myc
overexpressing cell lines were mock treated or infected with increasing amounts of N-MLV luc. Forty-eight hours after infection, luciferase activity was
measured. One representative experiment of four independent experiments is shown. F. The CRFK empty vector control and the various TRIM5a-Myc
overexpressing cell lines were mock treated or infected with increase dose of N-MLV luc. Forty-eight hours after infection luciferase activity was
measured. One representative experiment of three independent experiments is shown. Error bars indicate standard deviation among triplicates in the
same experiment.
doi:10.1371/journal.ppat.1002019.g005
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(Figure S4). Therefore, the mutations introduced on TRIM5a are
not altering its subcellular localization.
CA mutations altering the SUMO conjugation sites
reduce TRIM5a restriction
The above results show that SIM1 and SIM2 in TRIM5a are
required for restriction activity in the 293T SUMO-1-overex-
pressing and MDTF and CRFK TRIM5a overexpressing cell
lines. We wondered if TRIM5a SIMs are required for binding
SUMO-modified CA or another SUMO-modified cellular factor.
First we tested if TRIM5a is able to bind SUMO-1. We transiently
overexpressed FLAG-TRIM5a wild-type in 293T cells, and
cellular lysates were used for a GST-pull down assay with GST
or GST-SUMO-1 fusion proteins produced and purified from
bacteria. We found that although weakly, TRIM5a is in fact, able
to interact with SUMO-1 (Figure 7A).
Our laboratory has previously described that Mo-MLV CA
interacts with the SUMO E2 ligase UBC9, and undergoes
SUMO-1 conjugation. We have identified the domain of CA that
interacts with UBC9 and PIAS4/y, and those lysine residues
present in this domain and nearby that were required for CA
SUMO conjugation [54]. To test whether these features of CA
were involved in SUMO-1 restriction, we generated a series of
mutant versions of N-MLV in which CA lysine residues in and
near the UBC9 interaction were mutated to arginine (Figure 7B),
analogous to mutations previously tested in the context of Mo-
MLV. Although all the N-MLV luc mutant viruses showed
reduced infectivity, as was reported for the equivalent mutants of
Mo-MLV [54], they retained sufficient activity to allow us to infect
cells, score for luciferase activity and observe the difference
between restrictive and non restrictive cells (Figure S5).
We infected both the empty vector control and HA-SUMO-1-
overexpressing 293T cell lines with various mutant N-MLV luc
Figure 7. CA mutations altering putative SUMO conjugation site reduce SUMO-1 and TRIM5a-mediated restriction. A. The ability of
human TRIM5a to interact with SUMO-1 is shown by GST-pulldown. 293T cell were transiently transfected with an empty plasmid or a plasmid
encoding a FLAG-tagged version of human TRIM5a, forty-eight hours after transfection total extract were prepared and assayed for interaction with
GST or GST-SUMO1 produced in bacteria. Input corresponds to 5% of the amount used in the interaction assay. B. Amino acid sequence of the UBC9
binding region of CA protein. The lysine residues conserved between Mo-CA and N-CA are highlighted, and the consensus binding sequence is
underlined. The position and identity of the substituted amino acids in N-CA are indicated for each mutant. C. The 293T empty vector and HA-SUMO-
1 cell lines were infected with wild type N-MLV luc or N-CA mutant viruses. D. MDTF empty vector and wild-type human TRIM5a cell lines were
infected with wild-type N-MLV luc or the N-CA mutant viruses. Forty-eight hours after infection, luciferase activity was measured, and the fold
restriction between the two cell lines was calculated for different experiments, presented as average fold restriction. Error bars indicate standard
deviation among 6 different experiments. * indicates p,0.01.
doi:10.1371/journal.ppat.1002019.g007
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restriction as the ratio between the luciferase activities of these
cultures (Figure 7C and S5A). As previously observed, wild type N-
MLV was restricted an average of 8-fold by SUMO-1 overex-
pression. The K193R and K201,203R N-MLV mutants were still
restricted, but the restriction was reduced to 5- and 4-fold
respectively. Strikingly the K218R and K201,203,218R mutant
viruses were not significantly restricted (1.5 and 1.8 fold restriction
respectively) by SUMO-1 overexpression. This result indicates
that CA mutations altering the UBC9 interaction site, and lysines
required for SUMO conjugation reduced the SUMO-1 block to
N-MLV infection. Therefore, SUMO conjugation of CA is
required for the SUMO-1-enhanced TRIM5a restriction activity.
To determine the effect of CA mutations on TRIM5a
restriction when SUMO-1 is not overexpressed, we infected the
MDTF empty vector and TRIM5a-overexpressing cell lines with
either wild-type or CA mutant versions of N-MLV luc and
measured the luciferase activity in culture lysates. The fold
restriction was calculated as the ratio between the luciferase
activities observed upon infection of the empty vector and
TRIM5a cell lines. MTDF cells expressing TRIM5a restricted
wild-type N-MLV by an average of 166 fold over the control cells.
The K193R and K201,203R mutants were also profoundly
restricted and had no significant reduction of restriction (p.0.1)
when compared to wild-type virus. In contrast, the restriction of
the K218R and K201,203,218R mutants was significantly, though
only modestly, reduced (p,0.01) when compared to wild-type
virus (71 and 50 fold respectively) (Figure 7D). Thus, mutation of
the major UBC9 interaction site (K218) and the lysines required
for SUMO conjugation of CA (K218, K201 and K203) reduced
TRIM5a antiviral activity. These results, together with the
evidence that the TRIM5a SIM1 and SIM2 are required for
antiviral activity against N-MLV suggests that at least a portion of
the antiviral activity of TRIM5a is mediated through the binding
of its SIMs to SUMO-conjugated CA.
Discussion
In this study, we have identified the involvement of the SUMO
conjugation machinery in the TRIM5a mediated restriction of N-
MLV. Our findings indicate that overexpression of SUMO-1 in
293T and TE671 cells enhances an intrinsic block to N-MLV
infection of human cell lines (Figure 1C and 2C). We show that
this enhanced block is dependent on virus tropism (Figure 3A),
occurs before reverse transcription (Figure 3C), and can be
abrogated by pre-infection with restricted virus (Figure 3B). These
characteristics are shared by TRIM5a restriction of N-MLV in
human cells, and by RNAi-mediated knockdown of TRIM5a in
the SUMO-1 overexpressing cells, we confirmed that the
enhanced block of N-MLV infection is due to TRIM5a activity
(Figure 4C and D).
TRIM5a orthologues of primate and non-primate species have
restrictive activity against a variety of retroviruses [62–65]. The
four domains (RING, B-box, coiled-coil and B30.2) of TRIM5a
have been extensively studied in efforts to elucidate their functions
in retroviral restriction [21,25,27,32,66–68]. These studies have
revealed the importance of both the RING and B30.2 domains of
rhesus TRIM5a in the inhibition of HIV-1 infection [11] and the
requirement of the RING, B-box and B30.2 domains of human
TRIM5a in the inhibition of N-tropic MLV [32]. TRIM5a has
been found to bind to the retroviral capsid via its B30.2 domain
[25,26,58]. Several groups have proposed that TRIM5a leads to
an acceleration of the viral uncoating process, which results in
deleterious disassembly of the capsid structure and exposure of the
viral RNA to destructive cellular factors [26,64,69]. There is also
evidence that suggests a role for ubiquitination and proteasome-
mediated degradation of CA in TRIM5a-mediated restriction
[70,71]. There has been no report indicating a relationship
between the SUMO conjugation pathway and TRIM5a restric-
tion activity. We consider that TRIM5a SUMO-1 conjugation
could somehow enhance TRIM5a restriction activity. However,
we have not been able to demonstrate SUMO-1 modification of
TRIM5a, and in addition our data indicates that mutation of a
potential SUMO conjugation site does not affect TRIM5a
antiviral activity either in the 293T HA-SUMO-1 cell line
(figure 5C) or in the TRIM5a-expressing MDTF (figure 5E) or
CRFK cells (figure 5F), indicating that this is not the likely
mechanism of enhanced antiviral activity of TRIM5a upon
SUMO-1 overexpression. We also considered the possibility that
SUMO-1 overexpression impacts TRIM5a expression levels.
Although we cannot eliminate this possibility for the endogenous
protein, an overexpressed FLAG-tagged TRIM5a had very
similar levels of expression in control and HA-SUMO-1
overexpressing cells (Figure S1A), which argues against an
enhancement of TRIM5a protein levels as the mechanism of
increased activity upon SUMO-1 overexpression.
The ubiquitin and SUMO pathways have been described as
having an antagonistic relationship, but further studies have
revealed a more complex interplay between these pathways. There
are multiple reports that SUMO conjugation can act as a signal to
recruit E3 ubiquitin ligases, leading to proteasome-mediated
degradation of the modified protein. To date, the so-called
SUMO-targeted Ubiquitin ligase (STUbL) family has been
described in yeast, Dictyoselium, Drosophila, and mammals. Notably,
all known STUbL proteins have a RING finger domain and an
active SIM, which mediates the noncovalent binding to SUMO
[72,73 and reviewed in 74]. Analysis of the TRIM5a protein
sequence revealed three potential SIMs in the B30.2 domain. We
found that mutation of the first two hydrophobic residues of SIM1
and SIM2 to lysine had dramatic effects on TRIM5a restriction of
N-MLV. SIM1mut and SIM2mut versions of TRIM5a were not
able to fully restore TRIM5a antiviral activity in the HA-SUMO-
1/shRNA4 overexpressing cell line (Figure 5C) and had absolutely
no restriction activity in MDTF and CRFK cells (Figure 5E and
5F respectively). The same was observed in the rhesus TRIM5a
overexpressing cells (Figure 6B). Mutation of SIM3 had a more
moderate effect on TRIM5a restriction; cells expressing SIM3mut
were still able to restrict N-MLV, but not as effectively as the wild-
type protein. These results are consistent with a model in which
TRIM5a activity is partially mediated by SIMs binding to
SUMO-modified CA.
If TRIM5a is a novel STUbL, it would explain our observations
of the SUMO-1 antiviral effects in 293T cells and the current
model of a proteasome-dependent TRIM5a-mediated restriction.
SUMO-1 can be conjugated to Mo-CA in vivo [54], and the
amino acid sequence of the SUMO conjugation site in N-CA is
identical to that of Mo-CA. We can speculate that SUMO
conjugation to N-CA facilitates or stabilize TRIM5a binding via
the SIMs. With multiple SIMs, TRIM5a could either bind
multiple SUMO-1 conjugated viral CA proteins present in the
incoming virus, or one CA molecule with multiple SUMO
modifications. Once TRIM5a binds to the SUMO-CA, the RING
domain of TRIM5a could activate the proteasome-mediated
degradation of CA or other viral proteins associated with it,
leaving the viral RNA unprotected and vulnerable to cellular
factors. It is also possible that the mere binding of TRIM5a to the
SUMO-modified CA is sufficient to interfere with the viral life
cycle, which could explain why in the SUMO-1 overexpresing cell
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as the wild-type protein the restriction observed upon SUMO-1
overexpression.
TRIM5a belong to a large family of TRIM proteins that were
originally observed to oligomerize into high-order structures
localizing to specific compartments in the cytoplasm and nucleus
[75]. TRIM19, also known as PML, forms the so-called PML
nuclear bodies, which are important host antiviral defense
against DNA virus (for review see [76]). PML was shown to be
SUMOylated on 3 lysine residues and also contain a SIM.
Accordingly intramolecular interactions between the PML
SUMO and SIM were proposed to underlie PML nuclear
bodies formation and recruitment of partners [77,78]. Although
an appealing model, specific PML isoforms that do not contain
the SIM are able to form normal bodies [79] and still have
antiviral activity [80]. When expressed from transgenes,
TRIM5a has been reported to form large cytoplasmic bodies
[11,59]. We observe that TRIM5a mutants that lack the SIM
are still able to form cytosolic bodies, which is similar to the case
of the PML protein that do not contain a SIM, but in our case
this TRIM5a mutant proteins lack the antiviral activity.
TRIM5a bodies have been described as highly dynamic
structures that interact with cytoplasmic viral complexes
[60,81], and it could be possible that the mutations we have
introduced are affecting the dynamics of these structures, making
them incapable to get to the viral complexes. Also, if TRIM5a
cytosolic bodies are highly dynamic structures, the presence of
the SIMs may stabilize the binding to the incoming viral cores,
which are primarily recognized through the N tropism
determinants (arginine 110) on CA. It could be interesting in
further studies analyze the localization of TRIM5a SIM mutants
and viral complexes upon infection.
Our data showing that viruses with CA mutations in the
SUMO conjugation site and nearby lysines are not fully
restricted support the theory that TRIM5a SIMs bind SUMO-
CA. More importantly, mutant viruses containing the K218R
mutation, which removes the lysine in the major UBC9
interaction site, are poorly restricted relative to wild-type virus
in some settings (Figure 7C and 7D). While these mutants are
still restricted in the MDTF-TRIM5a cells (Figure 7D), this
could be due to other lysines acting as acceptor sites for SUMO
conjugation, and to the high levels of TRIM5a expression.
Portions of TRIM5a in the B30.2 domain have been described
as important for binding CA [26,58], and TRIM5a may be able
to bind CA molecules with reduced efficiency in the absence of
SUMOylation. The SUMO-conjugation sites of CA are located
in the C-terminal domain of the protein, and upon maturation
the C-terminal domain of CA migrates to fill the interstitial
spaces between hexamers in the N-terminal domain layer, in the
current model of MLV CA structure (Burns and Goff
unpublished data and [82]). This rearrangement of CA could
allow the SUMOylated lysines of CA to be exposed in the
surface of the incoming virus. It is possible that the TRIM5a
protein can recognize the arginine residue 110 of N-CA and the
SUMOylated lysines at the same time or that different TRIM5a
molecules can independently recognize each feature. Unfortu-
nately the exact location of the SUMO-conjugation sites of CA
in the mature lattice is still not available.
Earlier work has suggested that the SUMO modification of CA
is important for successful infection: MLV mutant viruses with
alterations in the UBC9 interaction site or mutations that abolish
SUMO conjugation are blocked in an early step of infection [54].
If SUMO conjugation of CA is an important step during viral
infection, is likely that innate immunity might take advantage of
this process to restrict viral infection. The presence of SIMs in
TRIM5a could be an adaptative advantage of this protein for its
antiviral activity. SIM1 and SIM2, which do have a role in human
and rhesus TRIM5a restriction of N-MLV, are located outside of
the variable regions, while SIM3 which does not have a role on
restriction activity is inside of the variable region 3. The location of
SIM1 and SIM2 suggest that they are important for TRIM5a
function and in fact several TRIM5a orthologs contain the SIMs
present in the human protein (Figure S3).
In conclusion, our data show that the SIMs of TRIM5a are
important for restriction of N-MLV, and that their mutation
abolishes antiviral activity. The presence of an intact UBC9
interaction site and lysines that potentially can be SUMO
modified in N-CA are required for full restriction by human
TRIM5a. We propose that TRIM5a SIMs increase affinity of
recognition of SUMO-modified CA. Further analyses are
required to determine if TRIM5a is indeed restricting virus as
a STUbL.
Materials and Methods
Cell lines
Human embryonic fibroblast (293T), Mus dunni tail fibroblast
(MDTF), human medulloblastoma cell line TE671 and Crandall
feline kidney (CRFK) fibroblast were maintained in Dulbeccos’s
modified Eagle medium supplemented with 10% fetal bovine
serum, 100 UI/ml penicillin and 100 mg/ml streptomycin. All
cells were cultured at 37uCi n5 %C O 2.
Plasmids, subcloning and mutagenesis
pCIG3-N and pCIG3-B express gag and pol from N-MLV and
B-MLV respectively [83]. pCMVI expresses gag and pol from NB-
MLV. p8.91 encodes gag and pol of HIV-1. pMD.G expresses the
vesicular stomatitis virus envelope glycoprotein [21]. pFBLuc
(Stratagene) is a reporter plasmid containing the firefly luciferase
coding sequence flanked by MLV-based LTRs. pCNCG is a
CMV-driven reporter plasmid containing the green fluorescent
protein (GFP) coding sequence flanked by MLV-based LTRs.
pQCXIH Retroviral vector (Clontech) is a bicistronic expression
vector that expresses an inserted gene along with the hygromicin
selection marker. pQCXIP Retroviral vector (Clontech) is a
bicistronic expression vector that expresses an inserted gene along
with the puromycin selection marker. pcDNA3xFLAG is a CMV-
driven expression vector that allows expression of N-terminal
FLAG epitope proteins [84]. SUMO-1 was subcloned from pSG5
His-SUMO-1 (gift from Dr. Anne Dejean of the Institut Pasteur).
SUMO-2 and SUMO-3 were subcloned from pCDNA4 His-
MaxC-SUMO-2 or HisMaxC-SUMO-3 (gifts from Dr. Yoshiaki
Azuma, The University of Kansas) into pQCXIH, such that the
His tag was replaced with the HA epitope. Human and rhesus
TRIM5a were subcloned from pMIP-TRIM5a (gift from Dr.
Jeremy Luban) [85] into pcDNA3xFLAG. Human TRIM5a
K10R and SIMs substitution mutants were generated by two-step
overlapping PCR and cloned into pcDNA3xFLAG. Human
TRIM5a wild type, K10R and SIMs mutants were subcloned
from pcDNA3xFLAG-TRIM5a vectors into pQCXIP, such that
the N-terminal FLAG epitope was replaced with a C-terminal
Myc epitope. FLAG rhesus TRIM5a wild type, K10R and SIMs
mutants were subcloned from pcDNA3xFLAG-TRIM5a vectors
into pQCXIP. The pCIG3-N mutant versions CA R110E, CA
K193R, CA K201,203R, CA K218R and CA K201,203,218R
were generated by site-directed mutagenesis using Quick Change
Lightning kit (Stratagene). Note: All primer sequences are
available upon request.
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Retroviruses for transduction were produced by transfection of
293T cells with 1 mg pMD.G, 1 mg pCMVI and 1.5 mg of either
pQCXIH,pQCXIH-HA-SUMO-1,pQCXIP,pQCXIP-TRIM5a
wild-type or mutant versions, using FUGENE (Roche). Viruses
were harvested 48 h after transfection, filtered (0.45 mm) and used
to infect 5610
5 cells in 100 mm dishes in the presence of 8 mg/ml
polybrene. 293T, MDTF and TE671 cells infected with vectors
delivering the hygro
r gene were selected in 200 mg/ml hygromycin.
Cells infected with vectors containing the puro
r gene were selected
either in 5 mg/ml puromycin (MDTF cells) or in 7.5 mg/ml
puromycin (CRFK cells). Lentiviruses for transduction were
produced by transfection of 293T cells with 1 mg pMD.G, 1 mg
p8.91 and 1.5 mg of pGIPz (Open Biosystems) or pGIPzTRIM5a
DNAs containing shRNAs #1t o#5 (Open Biosystems). Viruses
were harvested 48 h after infection, filtered (0.45 mm) and used to
infect 5610
4 293T HA-SUMO-1 cells in 35 mm dishes in the
presence of 8 mg/ml polybrene. Cells were selected in 200 mg/ml
hygromycin and 1.5 mg/ml puromycin.
Western blotting
Cells were lysed in 20 mM Tris-HCl (pH 8.0), 137 mM KCl,
10% glycerol, 1% NP-40 and Complete protease inhibitor (Roche)
or Reporter lysis buffer (Promega). Samples were then boiled in
56 sodium dodecyl sulphate (SDS) loading buffer, and the
proteins were resolved by SDS-polyacrylamide gel electrophoresis
(PAGE). After transfer to nitrocellulose membranes, the blots were
probed with mouse anti-b actin (Sigma), mouse anti-HA
(Covance), mouse anti-FLAG (Sigma) or mouse anti-c-Myc (Santa
Cruz Biotechnology).
Single-cycle infectivity assay
B-, NB- and N-tropic luciferase reporter viruses were produced
by transfection of 293T cells with 1 mg pCIG3-B or pCMVI or
pCIG3-N (the wild type or mutant versions), 1 mg pMD.G and
1.5 mg pFBluc or pCNCG (per 100 mm plate) using FUGENE
(Roche). Reporter virus stocks were harvested 48 h after
transfection, filtered (0.45 mm) and stored at 280uC. 293T
(3610
4 per well), MDTF (2.5610
4 per well), TE671 (2.5610
4
per well) and CRFK (3610
4 per well) cells were seeded in 24-well
plates and infected with MLV luc reporter viruses. For reactions
involving transient transfections, cells were transfected with 100 ng
of pcDNA3xFLAG or pcDNA3xFLAG-TRIM5a wild type or
mutant versions. Twenty-four hours post-transfection, cells were
infected with N-MLV luc virus. Forty-eight hours post-infection
cells were collected and assayed for firefly luciferase activity
(Promega) in a luminometer.
Analysis of viral DNA synthesized in vivo
Cells 293T (1610
5) plated in 35 mm dishes were infected with
N-MLV luc for six hours. Twenty-four hours post-infection, cells
were trypsinized, pelleted and total DNA was collected using
DNeasy Qiagen kit (Qiagen). Quantitative PCR (qPCR) analysis
was performed using primers to amplify the minus-strand strong
stop (MSS), 2-LTR circles (LTR-LTR junction) and luciferase
DNA as previously described [86].
Analysis of TRIM5a knock down
Cells were harvested and total RNA was extracted using
TRIZOL reagent (Invitrogen). 2 mg of total RNA per cell line was
used for reverse transcription reactions to produce cDNA using
random hexamers and SuperScript III kit (Invitrogen). 2 ml of each
cDNA was used for qPCR analysis of TRIM5a and GAPDH
transcript levels. Fold change was calculated using the relative
standard curve method.
GST-pull down assay
GST and the fusion protein GST-SUMO1 were produce in
Escherichia coli BL-21 (DE3) as previously described [87]. 293T cells
were transfected with 3 mg of pcDNA3xFLAG-humanTRIM5a or
the empty vector. Forty-eight hours after transfection the cells
were lysed on 20 mM Tris-HCl (pH 8.0), 137 mM KCl, 10%
glycerol, 1% NP-40 and Complete protease inhibitor (Roche)
20 minutes at 4uC, the lysate was clarified by centrifugation at
130006g for 10 minutes at 4uC. GST-pulldown assays were
performed using 100 ml of cell lysate and 2 mg of purified GST or
GST-SUMO1 and 20 ml of Glutathione Sepharose 4B (Amersham
biosciences) in binding buffer (20 mM Tris-HCl (pH 8.0),
100 mM KCl, 10 mM EDTA, 0.5 mM DTT, Complete protease
inhibitor) for 2 hours, the beads were washed 4 times with wash
buffer (20 mM Tris-HCl (pH 8.0), 100 mM KCl, 0.2% NP-40
10 mM EDTA, 0.5 mM DTT, Complete protease inhibitor), the
beads were resuspended with 40 ml of GLB2x, and the proteins
were resolved by SDS-PAGE. After transfer to nitrocellulose
membranes, the blots were probed with mouse anti-FLAG (Sigma)
or mouse anti-GST (Covance).
Accession numbers
SUMO-1: AACC5096.1
SUMO-2: P61956.2
SUMO-3: NP_008867.2
MoMLV: AF033811
N-tropic MLV gag-pol region: K01203.1
B-tropic MLV gag-pol region: K01204.1
TRIM5a: H.sapiens ABB90543, M. mulatta NP_0010228082
Supporting Information
Figure S1 SUMO-1 overexpression does not modified TRIM5a
protein levels. A. The 293T empty vector or HA-SUMO-1
overexpressing cells were transiently transfected with 100 ng of an
empty plasmid or plasmids encoding FLAG-tagged human
TRIM5a wild-type or the K10R, SIM1mut, SIM2mut and
SIM3mut versions. Forty-eight hours after transfection the cells
were lysed and the presence of the different TRIM5a proteins was
assayed by Western blot using an anti-FLAG antibody. The
presence of GAPDH was used as loading control. B. The levels of
the FLAG-TRIM5a proteins in the HA-SUMO-1 cell line were
quantified and expressed as relative values to the levels of FLAG-
TRIM5a in the control cell line; in both cases the protein level was
normalized to GAPDH. Error bars correspond to standard
deviation from 4 independent experiments.
(TIF)
Figure S2 K10R and SIM3 mutant block N-MLV infection
before reverse transcription. The MDTF empty vector control or
human TRIM5a wild-type, K10R or SIM3mut overexpressing
cell lines were infected with VSV-G-pseudotyped N-MLV luc.
Low molecular weight DNA was isolated twenty hours after
infection, and the amount of viral DNA synthesized in the infected
cells was measured by quantitative PCR. Primers specific for the
minus-strand strong stop (MSS) DNA (black bars), Luciferase gene
(grey bars) or LTR-LTR junction (white bars) were used. The
values were normalized to mitochondrial DNA and expressed as
fold over empty vector. Error bars indicate standard deviation
from 3 different experiments.
(TIF)
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primate orthologs. An alignment of the amino acid sequence of
TRIM5a B30.2 domain from several primates orthologs is shown.
The three variable regions (V1–V3) are depicted with horizontal
bars above the alignment. The SIMs are indicated in red letters.
Dashes represent gaps. The sequences were retrieved from protein
data bank and aligned using AlignX (Invitrogen). H.sapiens
(ABB90543), P. troglodytes (AAV91977), P. pygmaeus (AAV91984),
G. gorilla (AAV91981), S. syndactylus (AAV91980), M. mulatta
(NP_0010228082), C. guereza (AAV91978), P. nemaeus (AAV91979),
E. patas (V91985), M. fascicularis (BAD93339), C. tantalus
(AAT10388), C. aethiops (AAV91975), P. Anubis (AAV91976), A.
geoffroyi (AAV91987), L. logotricha (Q5D7H7), P. pithecia (AAV91986),
C. donacophilus (AAV919990), S. sciureus (AAV919888), S. labiatus
(AAV91989).
(TIF)
Figure S4 Mutations in TRIM5a do not change its subcellular
localization. The subcellular localization of rhesus TRIM5a stably
expressed in CRFK cells was assayed. Empty vector control or
TRIM5a overexpressing cells were grown on coverslips for
twenty-four hours and fixed in 3.7% formaldehyde in PBS. After
permeabilization with 1% triton X-100 the cells were incubated
with anti-FLAG M2 monoclonal antibody (Sigma) at a dilution of
1:500 and a secondary anti-mouse conjugated with Alexa Fluor-
488 (Molecular probes) at a dilution of 1:500. Vectashield
mounting medium with DAPI (Vector) was used. The cells were
visualized with a UPLSAPO 606 1.35-numerical aperture
Olympus oil immersion objective using a Olympus BX61
microscope fitted with a FV1000 FLUO laser scanning confocal
system. Image analysis was performed using MethaMorph
software.
(TIF)
Figure S5 CA mutations altering putative SUMO conjugation
site reduce viral infectivity. A. The 293T empty vector and HA-
SUMO-1 cell lines were infected with wild type N-MLV luc or N-
CA mutant viruses. B. MDTF empty vector and wild-type human
TRIM5a cell lines were infected with wild-type N-MLV luc or the
N-CA mutant viruses. Forty-eight hours after infection, luciferase
activity was measured. One representative of 6 different expe-
riments is shown. Error bars indicate standard deviation of
triplicates in the same experiment.
(TIF)
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